Medicare Enrolled
Dr. Amir Rasheed, M.D.
Hematology & Oncology · Baytown, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rasheed from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rasheed? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rasheed
Dr. Amir Rasheed is a hematology & oncology in Baytown, TX, with 18 years in practice. Based on federal Medicare data, Dr. Rasheed performed 60,432 Medicare services across 1,926 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rasheed received a total of $12,842 from 80 pharmaceutical and/or device companies across 684 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rasheed is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 15% volume in TX$ $12,842 industry payments
Medicare Practice Summary
Medicare Utilization ↗60,432
Medicare services
Top 15% in TX for hematology & oncology
1,926
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,357 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 44,600 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 3,440 | $6 | $15 |
| Hospital follow-up visit, moderate complexity | 2,193 | $64 | $115 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 2,000 | $2 | $12 |
| Injection, granisetron hydrochloride, 100 mcg | 1,961 | $0 | $2 |
| Complete blood count (CBC) with differential | 1,016 | $8 | $15 |
| Dexamethasone injection (steroid) | 850 | $0 | $1 |
| Office visit, established patient (20-29 min) | 796 | $66 | $120 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 729 | $49 | $150 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 646 | $16 | $55 |
| Office visit, established patient (30-39 min) | 370 | $96 | $170 |
| Initial hospital admission, moderate complexity | 343 | $105 | $250 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 233 | $23 | $81 |
| Drug injection, under skin or into muscle | 207 | $11 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 206 | $104 | $350 |
| Injection of additional new drug or substance into vein | 201 | $12 | $55 |
| Blood draw (venipuncture) | 157 | $8 | $10 |
| Injection, diphenhydramine hcl, up to 50 mg | 124 | $1 | $5 |
| Administration of chemotherapy into vein, each additional hour | 92 | $23 | $200 |
| New patient office visit (30-44 min) | 91 | $87 | $181 |
| Administration of additional new drug or substance into vein, 1 hour or less | 82 | $52 | $175 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 49 | $18 | $68 |
| Hospital follow-up visit, high complexity | 28 | $96 | $160 |
| New patient office visit (45-59 min) | 18 | $124 | $255 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.7% high complexity
88.8% medium
8.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,842
Total received (2018-2024)
Avg $1,835/year across 7 years
Top 27% in TX for hematology & oncology
80
Companies
684
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,432 (96.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$410 (3.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,064
2023$2,388
2022$1,783
2021$1,633
2020$1,430
2019$1,859
2018$1,686
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$1,418
Celgene Corporation
$887
Novartis Pharmaceuticals Corporation
$818
Merck Sharp & Dohme Corporation
$796
AstraZeneca Pharmaceuticals LP
$700
Incyte Corporation
$559
Eisai Inc.
$452
Lilly USA, LLC
$440
E.R. Squibb & Sons, L.L.C.
$434
GlaxoSmithKline, LLC.
$399
Daiichi Sankyo Inc.
$366
Janssen Biotech, Inc.
$339
Seagen Inc.
$312
Amgen Inc.
$268
Merck Sharp & Dohme LLC
$262
Astellas Pharma US Inc
$228
EMD Serono, Inc.
$175
SOBI, INC
$164
GENZYME CORPORATION
$161
EISAI INC.
$151
Allergan Inc.
$134
Regeneron Healthcare Solutions, Inc.
$132
Boehringer Ingelheim Pharmaceuticals, Inc.
$115
MorphoSys, US Inc.
$113
BeiGene USA, Inc.
$109
Taiho Oncology, Inc.
$100
PharmaEssentia USA Corporation
$100
Myovant Sciences Inc.
$97
Pharmacosmos Therapeutics Inc.
$94
TAIHO ONCOLOGY, INC.
$93
TESARO, Inc.
$88
AVEO Pharmaceuticals, Inc.
$87
CSL Behring
$85
Teva Pharmaceuticals USA, Inc.
$82
Dova Pharmaceuticals
$79
Clovis Oncology, Inc.
$79
Verastem, Inc.
$78
ARRAY BIOPHARMA INC
$78
Gilead Sciences, Inc.
$78
Octapharma USA, Inc.
$76
Genentech USA, Inc.
$75
Puma Biotechnology, Inc.
$75
Global Blood Therapeutics, Inc.
$74
Alexion Pharmaceuticals, Inc.
$73
Janssen Pharmaceuticals, Inc
$71
Azurity Pharmaceuticals, Inc.
$68
Dendreon Pharmaceuticals LLC
$63
Kyowa Kirin, Inc.
$63
Lexicon Pharmaceuticals, Inc.
$62
Ipsen Biopharmaceuticals, Inc
$61
Rigel Pharmaceuticals, Inc.
$60
TerSera Therapeutics LLC
$56
Bayer HealthCare Pharmaceuticals Inc.
$56
Aveo Pharmaceuticals, Inc.
$54
JAZZ PHARMACEUTICALS INC.
$52
Adaptive Biotechnologies Corporation
$47
SUN PHARMACEUTICAL INDUSTRIES INC.
$43
Akcea Therapeutics, Inc.
$41
CTI BioPharma Corp.
$41
Alnylam Pharmaceuticals Inc.
$37
Amneal Pharmaceuticals LLC
$37
AMAG Pharmaceuticals, Inc.
$35
Kite Pharma, Inc.
$34
Stemline Therapeutics Inc.
$31
Tactile Systems Technology Inc
$28
Iovance Biotherapeutics, Inc.
$26
SANOFI-AVENTIS U.S. LLC
$25
Myriad Genetic Laboratories, Inc.
$24
MEDIVATION FIELD SOLUTIONS LLC
$23
Pharming Healthcare, Inc.
$20
Seattle Genetics, Inc.
$19
Sobi, Inc
$19
Genmab U.S., Inc.
$19
Mirati Therapeutics, Inc.
$18
ImmunoGen, Inc.
$17
Sysmex Inostics Inc
$17
Exelixis Inc.
$15
Novo Nordisk Inc
$15
Secura Bio, Inc.
$12
NOVARTIS PHARMACEUTICALS CORPORATION
$11
Top 3 companies account for 24.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AVASTIN · AVYCAZ · Abraxane · Afstyla · Amtagvi · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Betaseron · CABOMETYX · CALQUENCE · CHANTIX · CYRAMZA · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · EMEND · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FARYDAK · FERAHEME · FLEXITOUCH · FOTIVDA · Fabhalta · Flexitouch Plus · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · MYRISK · Mavenclad · Monoferric · Nexavar · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · POTELIGEO · PROMACTA · PROVENGE · Padcev · Phesgo · Pomalyst · Quzyttir · REBLOZYL · RETACRIT · RETEVMO · RUCONEST · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TEGSEDI · TUKYSA · Tavalisse · Tazverik · Trodelvy · ULTOMIRIS · Ultomiris · VERZENIO · VIVIMUSTA · VONJO · VOTRIENT · VYXEOS · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XARELTO · XTANDI · Xermelo · Xospata · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $21 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
29
Per 100K population
0.6
County median income
$73,104
Nearest hospital
HOUSTON METHODIST BAYTOWN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Rasheed is a mixed practice specialist, with above-average Medicare volume (top 15% in TX), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Rasheed experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Rasheed performed 44,600 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rasheed receive payments from pharmaceutical companies?
Yes. Dr. Rasheed received a total of $12,842 from 80 companies across 684 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rasheed's costs compare to other hematology & oncologys in Baytown?
Dr. Rasheed's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rasheed) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Baytown
Browse hematology & oncologys in Baytown ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology